BDBing-Jun Dong

Bing-Jun Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bing-Jun Dong has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Jun-Hui Chen

    Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China

    1 shared publication
  • Paolo Saul Coghi

    Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China

    1 shared publication
  • Wan-Ying Zhang

    Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China

    1 shared publication
  • Xiao-Li Zheng

    Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China

    1 shared publication
  • Xing-Xing Fan

    Macau University of Science and Technology

    1 shared publication

Latest Publications

  • Open Access

    Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines

    by Wan-Ying Zhang, Xiao-Li Zheng, Paolo Saul Coghi, Jun-Hui Chen, Bing-Jun Dong, Xing-Xing Fan

    With the COVID-19 pandemic, the importance of vaccines has been widely recognized and has led to increased research and development efforts. Vaccines also play a crucial role in cancer treatment by activating the immune system to target and destroy cancer cells. However, enhancing the efficacy of cancer vaccines remains a challenge. Adjuvants, which enhance the immune response to antigens and improve vaccine effectiveness, have faced limitations in recent years, resulting in few novel adjuvants being identified. The advancement of artificial intelligence (AI) technology in drug development has provided a foundation for adjuvant screening and application, leading to a diversification of adjuvants. This article reviews the significant role of tumor vaccines in basic research and clinical treatment and explores the use of AI technology to screen novel adjuvants from databases. The findings of this review offer valuable insights for the development of new adjuvants for next-generation vaccines.